A share price of Verona Pharma Plc ADR [VRNA] is currently trading at $105.14, down -0.03%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRNA shares have gain 0.18% over the last week, with a monthly amount glided 11.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on July 14, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Wolfe Research started tracking the stock with Outperform rating on July 01, 2025, and set its price target to $170. On April 28, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $100 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $80 on April 21, 2025. ROTH MKM initiated its recommendation with a Buy and recommended $68 as its price target on January 10, 2025. Wells Fargo started tracking with a Overweight rating for this stock on October 03, 2024, and assigned it a price target of $50.
Verona Pharma Plc ADR experienced fluctuations in its stock price throughout the past year between $18.51 and $105.50. Currently, Wall Street analysts expect the stock to reach $120 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $105.14 at the most recent close of the market. An investor can expect a potential return of 14.13% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.16%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.9 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 105.08 points at the first support level, and at 105.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 105.24, and for the 2nd resistance point, it is at 105.34.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Verona Pharma Plc ADR [NASDAQ:VRNA] is 8.86. Also, the Quick Ratio is 8.73, while the Cash Ratio stands at 7.1. Considering the valuation of this stock, the price to sales ratio is 75.50, the price to book ratio is 39.50.
Transactions by insiders
Recent insider trading involved Fisher Andrew, General Counsel, that happened on Jun 16 ’25 when 80000.0 shares were sold. Chief Financial Officer, Hahn Mark W completed a deal on Jun 11 ’25 to sell 0.4 million shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 0.4 million shares on Jun 11 ’25.
